Please login to the form below

Not currently logged in
Email:
Password:

Transgene

This page shows the latest Transgene news and features for those working in and with pharma, biotech and healthcare.

Transgene slumps as viral cancer therapy fails phase 3 trial

Transgene slumps as viral cancer therapy fails phase 3 trial

French biotech Transgene has abandoned a phase 3 trial of its SillaJen-partnered liver cancer therapy after an interim analysis suggested almost no chance of a positive outcome. ... Transgene said in a statement that South Korean biotech SillaJen had

Latest news

  • AZ invests more in IO with Transgene oncolytic virus deal AZ invests more in IO with Transgene oncolytic virus deal

    However this candidate is based on Transgene’s proprietary next-generation viral platform. ... AstraZeneca has similar plans to combined Transgene’s oncolytic viruses withits in-house pipeline ofImmuno-oncology (IO) treatments.

  • Developing therapeutic cancer vaccines Developing therapeutic cancer vaccines

    Both vectors contain the transgenes for PSA and multiple T-cell co-stimulatory molecules. .

  • Sanofi to act as contract manufacturer for Transgene Sanofi to act as contract manufacturer for Transgene

    Sanofi has formed an innovative collaboration with fellow French company Transgene that will see it act at the biotech's contract manufacturing organisation (CMO). ... But in return for its investment Transgene will be its preferred customer for 15 years

  • Regional plans

    As part of the Institut Merieux group, Transgene would be well placed to be able to address the European market with JX 594 for the treatment of solid tumours. ... 181. Transgene/Jennerex ##. JX 594 for the treatment of solid tumours.

  • Jennerex and Transgene cancer partnership

    worldwide. Transgene will be responsible for development costs and clinical development in its licensed territories, pursuant to the JX-594 global development plan. ... Transgene will commercialise and hold the right to manufacture JX-594 in its agreed

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Other oncolytic viruses are coming through the pipeline, including SillaJen/Transgene’s Pexa-Vec for liver cancer and other solid tumours with trial results due between now and the end of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...